Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz' Clozaril

Executive Summary

Pennsylvania mental health groups sue the state's Department of Public Welfare in an Oct. 4 civil action to allow access to Clozaril by all schizophrenic patients under Medicaid. Currently, Pennsylvania uses a lottery system for Clozaril treatment that selects from those who have failed at least two to three other therapies. On Sept. 10, a Kansas federal court judge ruled that the Kansas Medicaid agency must provide prescription coverage for a schizophrenic patient who had failed other therapies. The Kansas court also ordered the inclusion of Clozaril on the formulary list of drugs covered by the Kansas Medicaid program.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS018188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel